Introduction
Lung cancer is the leading cause of cancer related death among men and women in the United States. In 2011 alone, a total of 221,130 new cases and 156,940 deaths were reported (1).
Eighty-five percent of these lung cancers are non-small cell lung cancers (NSCLC), a heterogeneous group comprised of mostly squamous cell carcinomas (SCC) and adenocarcinomas. Despite improvements in response to increasingly sophisticated combination therapy, approximately 40% of patients with stage I and 60% of stage II NSCLC will die within 5 years, mainly due to the development of distant metastases (2) .
In SCC of the lung, chromosome 3 aberrations are prevalent. Recurrent deletion on the 3p arm and gain on the 3q arm are present in the majority of cases (3, 4) . Chromosome 3q26-29 amplification represents a critical region of genomic alteration in lung SCC. It occurs in up to 70% of lung SCCs and is of significant magnitude (i.e., 2-10 fold increase in copy number) (5) .
The amplicon develops early in lung cancer development and persists at the metastatic stage (6) . Identification of genes driving the selection for the 3q26-29 amplicon has been a significant research focus during the last decade. Using array comparative genomic hybridization (CGH) and mRNA expression array technologies, a number of candidate driver genes in this amplicon have been identified and proposed to contribute to the development of lung cancer. These genes include PIK3CA (7, 8) , SOX2 (9), DCUN1D1 (10), TP63 (11) , EIF4G1 (12) , EVI1 (13) , THPO (14) , TERC (15) , ECT2 (16) , PRKCI (17) , EPHB3 (18) , MASP1 (18) and SST (18) .
Despite remarkable progress on candidate driver gene identification for this amplicon, no consensus exists as which are the drivers and what are their functional implications (9, 10) .
Moreover, existing studies tend to focus on a single gene in the focal region of amplification. It has been suggested that different genes in an amplicon may contribute synergistically to tumor progression (19, 20) . We therefore hypothesized that genomic amplification leads to increased expression of several key regulators in the 3q26-29 amplicon that cooperate with one another Author Manuscript Published OnlineFirst on August 1, 2013; DOI: 10.1158/1078-0432.CCR- to promote SCC tumor cell growth. To identify these key regulators, we took an integrative genomics approach as depicted in Fig. 1 . Although existing bioinformatics methods usually require paired copy number alteration (CNA) and gene expression data for the prioritization of candidate genes in an amplicon, in this study, we have developed and validated a simple but effective method for prioritizing candidate driver genes using expression data alone. This method allowed us to integrate seven independent data sets containing a total of 593 human primary tumor samples to identify 20 consensus candidate drivers in the 3q26-29 amplicon. To further filter for genes with potential functional connectivity, we used a network-based approach and identified a small protein interaction network consisting of SENP2, DCUN1D1, DVL3 and UBXN7, which are involved in post-translational modifications such as SUMOylation, neddylation and ubiquitination. Experimental interrogations demonstrated a role of the network in promoting cell proliferation and suggested potential regulatory relationships between SENP2, DCUN1D1 and DVL3. Moreover, patient stratification based on gene expression values of this three-gene signature provides potential useful information regarding the adjuvant chemotherapy benefit for patients with SCC of the lung.
Materials and Methods

Data sets
152 paired gene expression and copy number data for lung SCC were downloaded from TCGA (The Cancer Genome Atlas) portal (21) , in which gene expression data were from Agilent 244K whole genome expression array and copy number data were from Agilent CGH 415K array. from the JBR.10 trial) (26) , which only contained Stage I and Stage II patients. Only lung SCC samples from these data sets were included in this study. For each of the filtered data sets, the gene expression data were subjected to quantile normalization and standardized using a genewise Z-score transformation.
299 and 110 paired gene expression and copy number data for head and neck SCC and cervical SCC were also downloaded from TCGA portal, in which gene expression data were from Illumina HiSeq 2000 RNA Sequencing Version 2 analysis and copy number data were from Affymetrix Genome-Wide Human SNP Array 6.0 array.
Human protein interaction data were collected and integrated from HPRD, MINT, intact, REACTOME, BioGRID, and DIP in April 2010. Only experimentally determined interactions supported by publications were considered to assure the reliability of the network. The consolidated data set comprised 94,146 interactions involving 11,660 genes.
Calculating the amplification scores for TCGA copy number data
Based on the TCGA Level 2 data downloaded from the TCGA data portal, we identified the markers in the 3q26-29 regions for each sample and then calculated the average normalized log2 score for all these markers to get the amplification score for each sample.
Concordance index
Concordance index (27) was defined as the fraction of all pairs of subjects (e.g. gene expression samples or genes in the amplicon) whose predicted scores (e.g. average expression scores or correlation between gene expression and average expression score)
were correctly ordered among all subjects that can actually be ordered in the observed scores (e.g. amplification scores or correlation between gene expression and amplification score).
Research. 
Random walk analysis
NetWalker (http://bioinfo.vanderbilt.edu/netwalker) (30, 31) was used to run random walk analysis based on the integrated human protein-protein interaction network described above.
NetWalker identifies genes of potential biological importance based on the assumption that mechanistically important genes are likely to form tightly connected groups whereas other genes tend to be randomly distributed on the network. Using a set of genes as ''seeds'', NetWalker calculated a score for each gene in the network based on its overall proximity to the seed genes, where the proximity is measured by the random walk similarity (32 significant global p value indicates a non-random association between the gene and the input seeds, whereas a significant local p value ensures that the significant association is not simply due to network topology.
Cell Cultures
Six human lung squamous carcinoma cell lines H520, HCC95, H2882, HCC15, H157 and SW900, four human lung adenocarcinoma cell lines H1819, H1648, A549 and H23, were purchased from the American Type Culture Collection (Manassas, Virginia, USA). Lung cancer cell lines were maintained in RPMI with 10% fetal bovine serum (FBS). All cells were grown in 1 mM Penicillin/streptomycin. 
RNAi knock down assays
Cell Viability Assay
Research. Lung cancer cells were transiently transfected in 96-well plates with target siRNA or negative control siRNA as described above. The CellTiter96 AQ One Solution assay (Promega, Madison, WI) was then performed following the manufacturer's instructions or as previously described (34) on the wells post transfection at 3 or 6 days. A representative viability experiment is shown in fold change that was normalized to negative siRNA control group with average standard deviation (s.d.).
Immunoblot Analysis
Rabbit anti-SENP2 antibody (HPA029248) was purchased from Sigma-Aldrich (St. Louis, MO).
Rabbit anti-UBXD7 (AB10037) was from Millipore (Billerica, MA). Rabbit Dishevelled 3 antibody (GTX102509) and rabbit DCUN1D1 antibody (GTX116558) were from Genetex (Irvine, CA). Western blotting was done using standard procedures as described in our previous study (33) , with detection using the enhanced chemiluminescence system (Thermo Scientific, Waltham, MA). Antibody dilutions for immunoblotting were 1:1,000. The blots were reprobed with an anti-β-Actin antibody (Sigma-Aldrich) to correct for protein loading differences. Anti-rabbit secondary antibody was purchased from Promega (Madison, WI).
Results
Predicting 3q26-29 gene amplification level using gene expression data
Correlation between gene expression and regional amplification level has been widely used to prioritize candidate driver genes in a predefined amplicon because mRNA overexpression can better translate the effect of elevated copy number to tumor progression and offer biological insights that are closer to levels of protein expression and function (35) . This approach requires paired CNA and gene expression data, but many large-scale lung SCC studies, including those with available clinical end points, comprise only gene expression data. Therefore, we first investigated the possibility of using gene expression data alone to predict 3q26-29 gene amplification level and prioritize candidate driver genes in the region.
Using the TCGA data set with paired CNA and gene expression data (36), we examined whether gene amplification directly contribute to increased mRNA expression in 152 lung SCC tumor samples. We first estimated a 3q26-29 amplification score for each sample based on the CNA data (Supplementary Table S1 ) and then co-visualized CNA and gene expression data in the Integrative Genomic Viewer (IGV, http://www.broadinstitute.org/igv/home), with the samples in both data sets ordered based on the 3q26-29 amplification score. As shown in Fig.   2A and 2B, although 3q26-29 amplification is prevalent, different samples demonstrated different levels of amplification. Samples with higher level of amplification also showed relatively higher expression for genes in this amplicon. We also found that most genes in this amplicon showed similar expression pattern, suggesting that genomic amplification contributes directly to an increase in mRNA gene expression. Next, we calculated the Spearman correlation coefficient between amplification scores and expression values for each gene in the expression data. Genes in the 3q26-29 regions were significantly better correlated with the amplification score compared to genes outside the region (p<2.2e-16, Fig. 2C ). Therefore, we reasoned that the amplification level of a chromosomal region could be inferred based on the expression of genes within the region.
Using TCGA gene expression data, we calculated an average gene expression score for each sample based on all genes in the 3q26-29 amplicon (Supplementary Table S1 ). The average expression score was significantly correlated with the amplification score derived from the copy number data (Spearman correlation r = 0.94 and p < 2.2E-16) and the concordance index (Cindex) between the two scores was 89.4% ( Fig. 2D) , demonstrating the validity of using the average expression score to predict the regional amplification level. We also ordered the samples by average expression scores and visualized the copy number data in the IGV. As shown in Supplementary Fig. S1 , the magnitude of 3q26-29 amplification clearly declined with the decreasing of the average expression score.
Finally, we compared the correlation between gene expression and amplification level (cor_exp_amp) with the correlation between gene expression and average expression score (cor_exp_ave) for each gene in the 3q26-29 amplicon (Supplementary Table S2 ). We found high consistency between the two types of correlations (Spearman correlation r = 0.95 and p<2.2E-16; concordance index = 90.6%, Fig. 2E ), providing clear support for using the correlation between gene expression and average expression score to prioritize candidate driver genes. Meanwhile, we found that previously reported candidate driver genes had a wide spread along the diagonal (Fig. 2E) , suggesting that many of them are not supported by the TCGA data, and a consensus conclusion on the driver genes at the 3q26-29 amplicon requires integrative analysis of data from multiple patient cohorts.
Integrative identification of candidate driver genes
The above results opened the possibility to estimate sample-specific amplification level and prioritize candidate driver genes using gene expression data alone. Therefore, we applied the method to another six independent lung SCC gene expression data sets available in the public domain (Supplementary Table S3 ) and estimated sample-specific amplification levels (Supplementary Table S4 -9) . We integrated all seven data sets to identify genes that were consistently overexpressed in the 3q26-29 amplified samples as candidate drivers of this amplicon. We first ranked genes based on the correlation between gene expression and sample amplification score for the TCGA data set or based on the correlation between gene expression and average expression score for other six data sets, respectively. Then, using the N-dimensional order statistic we combined the seven ranked lists to calculate a Q statistic and corresponding P value (see details in the Method section), which represents the random Table S10 ). Under an FDR of 1%, 20 genes were identified as candidate drivers (Table 1) . Because 3q26-29 amplicon is also present in SCC from other sites such as head and neck (37) and cervical (38) , we tested whether these 20 genes were also candidate drivers in other SCC. Based on the paired gene expression and copy number data in TCGA (see Materials and Methods), we calculated the correlation between gene expression and 3q26-29 amplification level for these 20 genes in head and neck SCC and cervical SCC. As shown in Supplementary Table S11 and S12, gene expression for all 20 genes were significantly correlated with 3q26-29 amplification level (for head and neck SCC, Spearman correlation p<1.27E-24; for cervical SCC, Spearman correlation p<7.31E-07), implying the validity of these 20 genes as candidate drivers in SCC.
Co-localization of candidate driver genes in a focal region of amplification suggests that coordinate amplification and overexpression of some of these genes might be required to alter specific mechanisms and eventually provide a growth advantage to cells that overexpress them (19, 20) . Therefore, using the 20 candidate driver genes as ''seeds'', we applied NetWalker (30) to identify genes that might function together in a coordinated manner (see details in the Methods section). Controlling both local and global p value sat the 0.01 level, we identified four out of the 20 candidate genes (SENP2, DCUN1D1, DVL3 and UBXN7) that are involved in a small, connected network with 13 significant nodes (Fig. 3) . Many genes in the network are involved in SUMOylation, neddylation and ubiquitin pathways.
Functional implications of four candidate drivers in SCC.
Prior work has established the oncogenic role of DCUN1D1 (defective in cullin neddylation 1 domain containing 1, also known as SCCRO or squamous cell carcinoma-related oncogene)
being an important component of the neddylation E3 complex in SCC (10, 39) . In contrast, the Table S13 ).
We next assessed the effect on lung cancer cell growth by knocking down the four proteins expression. We measured the proliferation of H520 cells with siRNAs against four genes respectively or scramble control siRNAs over 3 days and 6 days (Fig. 4B) . The silencing of the four proteins lead to the cell growth inhibition at varied degrees (20%-40% inhibition), among which, knocking down SENP2 resulted in most significant inhibition (40%). Interestingly, we found that cells with SENP2 knockdown induced the downregulation of DCUN1D1 and DVL3, but not UBXN7 (Fig. 4C) . In contrast, knockdown of DCUN1D1, DVL3 or UBXN7 did not lead to downregulation of SENP2 protein expression (Fig. 4D) . The same findings were confirmed in another 3q amplified cell line HCC95 but not in A549 which doesn't harbor 3q amplicon ( Supplementary Fig. S2 ).
Three-gene signature to predict adjuvant chemotherapy sensitivity in SCC patients
To evaluate the potential clinical significance of the computationally predicted network and experimentally supported driver genes, we tested whether a gene expression signature with the three genes (SENP2, DCUN1D1 and DVL3) could inform patient prognosis and treatment
Research. response. Based on the average of standardized expression levels of the three genes, we classified 52 patients from an independent data set (GSE14814) into two groups: a "highexpression" group with above median expression of the genes and a "low-expression" group with below median expression of the genes. For each group, we further separated patients into two subgroups based on whether they received adjuvant chemotherapy.
As a baseline comparison (i.e., for patients who did not received adjuvant chemotherapy), the high-expression group had a relatively shorter survival outcome compared with the lowexpression group (Fig. 5, red Fig. S3 ). We also performed survival analysis by stratifying patients based on each of the three genes individually. As shown in Supplementary Fig. S4 , stratification based on all three genes outperformed those based on individual genes, suggesting that cooperation of the three genes may play important role in cancer therapy. In this report, we investigated the functional implications of the chromosome 3q amplicon in lung SCC. We demonstrate that 1) a simple but effective method can be used to estimate sample-specific amplification level and prioritize candidate driver genes using expression data alone; 2) data fusion and network analysis techniques enable data integration across different studies and among different genes, allowing identification of driver genes that are supported by multiple studies and involved in a common biological theme; 3) all four computationally inferred driver genes including SENP2, DCUN1D1, DVL3 and UBXN7 were experimentally proven to regulate cellular proliferation in lung squamous cancer cells that harbor the amplicon and three of them (SENP2, DCUN1D1 and DVL3) might be functionally related to one another; and 4) the three-gene signature may be predictive of response to conventional chemotherapy in SCC. abundant in public databases such as the Gene Expression Omnibus (GEO). Thus, our method could have a general application in predicting amplification level and candidate driver genes in predefined amplicons for other cancer types.
In our study, we used the average expression score of all genes in the 3q26-29 amplicon to predict 3q26-29 amplification level. Although chromosomal amplification directly contributes to an increased mRNA expression level of genes in the amplified region (see Fig. 2A ), only 110 out of the 164 genes in this region showed significant correlation with the amplification score (Spearman p value<0.01). Moreover, even genes with significant correlations also showed different levels of correlation (Spearman correlation r ranging from 0.87 to 0.21). Thus, it is possible that expression of some genes may better represent genomic amplification than others. To test this possibility, we extracted the first principal component (PC) from gene expression data for all genes in the amplicon and used the first PC as an alternative approach to estimate the level of amplification. However, the results based on first PC were very similar to that based on all genes (data not shown), suggesting the validity of using average expression score of all genes in an amplicon as an easy method for estimating amplification level.
It is generally believed that regions of recurrent genome CNA harbor genes that are essential to cancer progression, nevertheless many functional studies focus on identifying a single candidate driver gene in the region of CNA responsible for cancer progression. It has been suggested that multiple genes from an amplicon may cooperatively promote tumorigenesis (20, 40) . Thus, in our study, we used network-based analysis to identify genes that might function in a coordinated manner. Through integrated computational network analysis and experimental interrogation, we identified three genes that may function together to promote tumor cell growth. These genes are involved in SUMOylation, neddylation or ubiquitination pathway.
Recently, the functional crosstalk between these similar pathways has emerged (41).
Nevertheless, how three pathways contribute to lung SCC development remains to be investigated.
Our experimental data suggest that SENP2 may regulate the expression of DCUN1D1 and DVL3. SENP2 belongs to Sentrin/SUMO-specific proteases family and has diverse function via SUMOylation or deSUMOylation in human cells (11) . In cancer cell, components of the SUMOylation or deSUMOylation machinery are enhanced or reduced (42) . In lung SCC cells, SENP2 has highest prevalence of amplification compared to other SENP family members ( Supplementary Fig. S5 ), further supporting its key role in lung SCC development. Whether and how SENP gene expression levels disturb SUMO homeostasis and contribute to lung SCC cancer development and progression are yet to be determined. Many SUMOmodified proteins function in regulation of transcription, chromatin structure, maintenance of the genome, and signal transduction (41) . MDM2-p53 is most well-studied SUMOmodified proteins. SENP2 promotes the deSUMOylation of Mdm2, contributing to the p53-dependent regulations (43) .
Interestingly, the tumour suppressor p53 has been shown to be modified at its C-terminus with ubiquitin, SUMO and NEDD8, although the consequence undergoing these post-translational modifications may differ (44) . Notably, NEDD8 is conjugated to three lysines within the Cterminus of p53 through the E3 ligase activity of MDM2 (45), adding another mechanism by which MDM2 inhibits p53 activity. DCUN1D1 is novel identified NEDD8 E3 complex component and has been proposed to an oncogene in lung SCC (10, 39) . Mechanistically, DCUN1D1 binds to the components of the neddylation pathway consisting of Cullin-ROC1, Ubc12 and CAND1 to promote cullinneddylation via releasing the inhibitory effects of CAND1 (39) . It is unclear how neddylation is regulated and how many oncogenic neddylated targets exist in cancer cell. Our data showed that knocking down SENP2 using siRNA leads to the downregulation of 
DCU1ND1, prompting us to that propose DCU1ND1 might be a potential SUMO-modified target regulated by SENP2 in lung SCC, a mechanism similar to SENP2-MDM2 pathway.
Disheveled (DVL) is an essential scaffold protein that transduces both the canonical (β-catenin-dependent) and the non-canonical (β-catenin-independent) Wntignaling pathways (46) . Activated DVL3 promotes Wnt/beta-catenin activation and undergoes KLHL12-Cul3 mediated ubiquitination for degradation (47) . Wnt-β-catenin pathway is disregulated in lung cancer (48) and may lead to new treatment strategies (49) . Dvl3 overexpression has also been found in NSCLC, and once silenced, inhibition of cellular proliferation is observed (50) . SENP2 negatively modulating β-catenin via its deSUMOylation activity in Hepatocellular Carcinoma Cell (51) and colon cancer cells (52) . It is suggested that non-canonical Wnt/PCP pathway but not canonical Wnt /β-catenin was enhanced in lung SCCs (5) . Our data showed that SENP2 knock-down leads to DVL3 downregulation. Therefore, we hypothesize that SENP2 may regulates β-catenin through DVL3 dependent or independent mechanisms in lung SCC cells and this will be tested in the context of future studies. Thus, unlike previous studies that identify individual genes from the 3q26-29 amplicon, the three genes identified in this study may represent a common biological mechanism that provides growth advantage to tumors harboring the amplicon.
Our survival analysis further supports potential importance of these three genes in lung SCC patient prognosis and particularly, response to adjuvant chemotherapy. Despite the small sample size of the patient cohort used for survival analysis, we observed distinct response to adjuvant chemotherapy for patients with high and low level expression of the three genes, respectively and independently of the disease stage. Unfortunately, no publically available datasets in SCC with annotated clinical outcomes were identified to confirm our preliminary data. Upon further validation in independent cohorts of patients with NSCLC, the three-gene 
